Reporting remotely on findings presented at ESMO Breast Cancer Virtual Meeting 2020, Guy Jerusalem comments on practice changing studies in pretreated patients with HER2+ advanced breast cancer, focusing on the important risk of brain metastasis in this population.
He firstly showed the results from the DESTINY-Breast01 trial subgroup analysis of patients with an history of CNS metastasis, treated with trastuzumab deruxtecan. Secondly, he discusses the results from the HER2CLIMB trial testing the addition of a tyrosine kinase inhibitor, tucatinib to trastuzumab plus capecitabine combined therapy, in HER2+ metastatic breast cancer patients with or without CNS metastasis at study inclusion.
Abstracts:
- 138O - CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
- 137O - Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)